ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 633,66
1,27%
Dow Jones
39 331,85
0,41%
DAX
18 334,99
1,00%
Brent Oil
86,125
-0,37%
Bitcoin
60 513,62
-2,44%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Virios Therapeutics Inc (VIRI)

  7. Virios Therapeutics Inc (VIRI) Actualités

VIRI

Virios Therapeutics (VIRI)

Virios Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VIRI
DateHeureSourceTitreSymboleSociété
20/06/202415h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
22/05/202419h30GlobeNewswire Inc.Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
20/05/202422h05Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VIRIVirios Therapeutics Inc
20/05/202402h53GlobeNewswire Inc.Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
17/05/202422h10GlobeNewswire Inc.Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
10/05/202416h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
09/05/202413h45GlobeNewswire Inc.Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
02/05/202415h15GlobeNewswire Inc.Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:VIRIVirios Therapeutics Inc
26/03/202414h15GlobeNewswire Inc.Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
08/03/202423h00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:VIRIVirios Therapeutics Inc
01/03/202415h10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRIVirios Therapeutics Inc
29/02/202415h15GlobeNewswire Inc.Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VIRIVirios Therapeutics Inc
28/02/202419h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
28/02/202415h15GlobeNewswire Inc.Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesNASDAQ:VIRIVirios Therapeutics Inc
02/02/202422h31Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VIRIVirios Therapeutics Inc
22/01/202415h33Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VIRIVirios Therapeutics Inc
22/01/202415h00GlobeNewswire Inc.Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
02/01/202413h05GlobeNewswire Inc.Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
13/11/202313h05GlobeNewswire Inc.Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
06/11/202313h05GlobeNewswire Inc.Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023NASDAQ:VIRIVirios Therapeutics Inc
12/10/202313h05GlobeNewswire Inc.Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023NASDAQ:VIRIVirios Therapeutics Inc
18/09/202313h05GlobeNewswire Inc.Virios Therapeutics Announces Termination of At-The-Market Sales AgreementNASDAQ:VIRIVirios Therapeutics Inc
12/09/202313h05GlobeNewswire Inc.Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023NASDAQ:VIRIVirios Therapeutics Inc
14/08/202313h05GlobeNewswire Inc.Virios Therapeutics Announces Halt to At-The-Market Offering SalesNASDAQ:VIRIVirios Therapeutics Inc
10/08/202313h05GlobeNewswire Inc.Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
09/08/202313h05GlobeNewswire Inc.Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for FibromyalgiaNASDAQ:VIRIVirios Therapeutics Inc
03/08/202322h05GlobeNewswire Inc.Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023NASDAQ:VIRIVirios Therapeutics Inc
17/07/202313h05GlobeNewswire Inc.Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept StudyNASDAQ:VIRIVirios Therapeutics Inc
14/07/202322h12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VIRIVirios Therapeutics Inc
20/06/202320h07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VIRIVirios Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRI

Dernières Valeurs Consultées

EU
AF
Air FranceKLM
NYSE
MCD
McDonalds
EU
ML
Michelin
NYSE
JPM
JP Morgan Chase
EU
EN
Bouygues
EU
VIV
Vivendi
NASDAQ
AAPL
Apple
USI
USTECH100
US Tech 100
EU
DG
Vinci
COIN
BTCUSD
Bitcoin
EU
RNO
Renault
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés